Abstract：Type 2 diabetes mellitus is closely associated with non-alcoholic fatty liver disease (NAFLD), which is the most prevalent chronic liver disease worldwide. Currently, the only validated treatment for NAFLD is lifestyle intervention. Glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors, collectively termed incretin-based therapies, represent two of the most widely used classes of novel antidiabetic drugs. A number of studies of human trials have evaluated the effects of incretins on liver fat content and suggest that the treatment could represent a new alternative for NAFLD management. In this paper, the main clinical studies regarding the effects of incretins on NAFLD are reviewed.
[1] Fan JG，Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China [J]. J Hepatol，2009，50（1）：204-210.
[2] Vanni E，Bugianesi E，Kotronen A，et al. From the metabolic syndrome to NAFLD or vice versa [J]. Dig Liver Dis，2010，42（5）：320-330.
[3] Cusi K. Nonalcoholic fatty liver disease in type 2 diabetes mellitus [J]. Curr Opin Endocrinol Diabetes Obes，2009， 16（2）：141-149.
[4] Bae EJ. DPP-4 inhibitors in diabetic complications：role of DPP-4 beyond glucose control [J]. Arch Pharm Res，2016， 39（8）：1114-1128.
[5] Khoo J，Hsiang J，Taneja R，et al. Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight，liver fat and liver function in obese patients with non-alcoholic fatty liver disease：a pilot randomized trial [J]. Diabetes Obes Metab，2017，19（12）：1814-1817.
[6] Armstrong MJ，Gaunt P，Aithal GP，et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis（LEAN）：a multicentre，double-blind，randomised，placebo-controlled phase 2 study [J]. Lancet，2016，387（10019）：679-690.
[7] Petit JM，Cercueil JP，Loffroy R，et al. Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes. The Lira-NAFLD study [J]. J Clin Endocrinol Metab，2017，102（2）：407-415.
[8] Eguchi Y，Kitajima Y，Hyogo H，et al. Pilot study ofliraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients （LEAN-J）[J]. Hepatol Res，2015，45（3）：269-278.
[9] Ohki T，Isogawa A，Iwamoto M，et al. The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglit-azone [J]. Scientific World Journal，2012，2012（7624）：496 453.
[10] Tang A，Rabasa-Lhoret R，Castel H，et al. Effects of insulin glargine and liraglutide therapy on liver fat as measured by magnetic resonance in patients with type 2 diabetes：a randomized trial [J]. Diabetes Care，2015，38（7）：1339-1346.
[11] Smits MM，Tonneijck L，Muskiet MHA，et al. Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes：a randomised placebo-controlled trial [J]. Diabetologia，2016，59（12）：2588-2593.
[12] Eng J，Kleinman WA，Singh L，et al. Isolation and characterization of exendin-4，an exendin-3 analogue，from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas [J]. J Biol Chem，1992，267（11）：7402-7405.
[13] Kenny PR，Brady DE，Torres DM，et al. Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis：a case series [J]. Am J Gastroenterol，2010，105（12）：2707-2709.
[14] Dutour A，Abdesselam I，Ancel P，et al. Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes：a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy [J]. Diabetes Obes Metab，2016，18（9）：882-891.
[15] Cuthbertson DJ，Irwin A，Gardner CJ，et al. Improved glycaemia correlates with liver fat reduction in obese，type 2 diabetes，patients given glucagon-like peptide-1（GLP-1） receptor agonists [J]. PloS One，2012，7（12）：e50 117.
[16] Sathyanarayana P，Jogi M，Muthupillai R，et al. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes [J]. Obes Silver Spring Md，2011，19（12）：2310-2315.
[17] Seko Y，Sumida Y，Tanaka S，et al. Effect of dulaglitide for 12 weeks in biopsy-proven NAFLD patients with type 2 diabetes in Japan [J]. Hepatol Res，2017，47（11）：1206-1211.
[18] Gluud LL，Knop FK，Vilsbøll T. Effects of lixisenatide on elevated liver transaminases：systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes [J]. BMJ Open，2014，4（12）：e005 325.
[19] Iwasaki T，Yoneda M，Inamori M，et al. Sitagliptin as a novel treatment agent for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus [J]. Hepatogastroenterology，2011，58（112）：2103-2105.
[20] Fukuhara T，Hyogo H，Ochi H，et al. Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus [J]. Hepatogastroenterology，2014，61（130）：323-328.
[21] Arase Y，Kawamura Y，Seko Y，et al. Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease [J]. Hepatol Res，2013，43（11）：1163-1168.
[22] Mashitani T，Noguchi R，Okura Y，et al. Efficacy of alogliptin inpreventingnon-alcoholic fatty liver disease progression in patients with type 2 diabetes [J]. Biomed Rep，2016，4（2）：183-187.
[23] Macauley M，Hollingsworth KG，Smith FE，et al. Effect of vildagliptin on hepatic steatosis [J]. J Clin Endocrinol Metab，2015，100（4）：1578-1585.
[24] Cui J，Philo L，NguyenP，et al. Sitagliptin vs. placebo for non-alcoholic fatty liver disease：a randomized controlled trial [J]. J Hepatol，2016，65（2）：369-376.
[25] Yilmaz Y，Yonal O，Deyneli O，et al. Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis [J]. Acta Gastroenterol Belg，2012，75（2）：240-244.
[26] Miyazaki M，Kato M，Tanaka K，et al. Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism [J]. Mol Med Rep，2012，5（3）：729-733.
2018, Vol. 15 
京公网安备 11010502046598号